BioLife Solutions (BLFS) Investor Presentation - Slideshow

Company Overview - BioLife Solutions aims to facilitate basic and applied research and the commercialization of new therapies by supplying solutions that maintain the health and function of biologic source material and finished products during manufacturing, storage and distribution[5] - The company's mission is to be a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets[5] - BioLife Solutions gained over 700 new direct customers in 2021[14, 24] - In 2021, marquee global distributors sold the company's biopreservation media products to over 4,200 unique end customers[14, 24] Financial Performance and Guidance - BioLife Solutions experienced year-over-year revenue growth of 148%[14] - The company's 2022 revenue guidance projects total revenue between $1595 million and $171 million, representing growth of 34% to 44%[20] - The company is aiming for total revenue exceeding $250 million, adjusted gross margin greater than 50%, and adjusted EBITDA margin greater than 30% by 2024[22] Market and Strategy - Regenerative medicine funding reached $231 billion in 2021, up 16% from 2020[29] - The company's biopreservation media is embedded in over 530 customer clinical applications[14, 40] - BioLife Solutions is pursuing an acquisitive growth strategy, targeting synergistic products and technologies in the cell and gene therapy space[58, 60]